Home › Funds › Vanguard › Vanguard Health Care Index Fund
Fund family: Vanguard · Filed by VANGUARD WORLD FUND (CIK 52848) · SEC series S000004450
Share classes and tickers: VHT (C000012223), VHCIX (C000012222)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 4,370 with, 1,305 against, 40 abstentions (not counted as with management); 12 items carried no recommendation; 682 split votes are in neither count. Shareholder proposals: 2 FOR, 36 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Vanguard’s manager page (1,379,791 ballot items across 136 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Vanguard | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 91.8% | 5,580 | 94.5% | 1,082,514 |
| Backed environmental and social shareholder proposals at US companies | n/a | 9 | 0.9% | 6,718 |
Each ballot item this fund voted is set against the votes of the other Vanguard funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Vanguard funds on 5 items (0.1% of the 4,552 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Vanguard funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | 2026-06-11 | To approve, by non-binding advisory vote, the resolution approving Named Executive Officer compensation. | Against | FOR — 4 of 5 Vanguard funds | Against | Approved, 51.2% support |
| Merck & Co., Inc. | 2026-05-26 | Election of Directors: Patrick F. Russo | For | AGAINST — 14 of 25 Vanguard funds | For | — |
| GoodRx Holdings, Inc. | 2026-06-16 | Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | Against | FOR — 7 of 11 Vanguard funds | Against | Passed (calculated), 99.0% support |
| Hologic, Inc. | 2026-02-05 | A proposal to approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to the named executive officers of the Company in connection with the transactions contemplated by the merger agreement, including consummation of the merger. | Against | FOR — 12 of 22 Vanguard funds | Against | — |
| Quantum-Si Incorporated | 2026-05-15 | To approve, by a non-binding, advisory vote, the compensation of our named executive officers, as disclosed in this proxy statement | Against | FOR — 5 of 9 Vanguard funds | Against | — |
Download all 5 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 98.4% of this fund’s 5,715 such votes could be given a sector; the other 94 (1.6%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 5,008 | 1,144 | 22.8% |
| Industrials | 293 | 83 | 28.3% |
| Technology | 148 | 22 | 14.9% |
| Consumer Discretionary | 128 | 29 | 22.7% |
| Consumer Staples | 36 | 15 | 41.7% |
| Finance | 8 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 5,083 | 1,184 |
| Audit-related | 477 | 36 |
| Say-on-Pay | 452 | 0 |
| Compensation | 236 | 37 |
| Corporate Governance | 104 | 27 |
| Capital Structure | 53 | 8 |
| Extraordinary Transactions | 31 | 3 |
| Shareholder Rights and Defenses | 16 | 1 |
| Other Social Issues | 5 | 5 |
| Environment or Climate | 3 | 3 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $6.9B | 14 | 6 |
| Johnson & Johnson | April 23, 2026 | $4.0B | 27 | 13 |
| AbbVie Inc. | May 8, 2026 | $3.1B | 13 | 5 |
| UnitedHealth Group Incorporated | June 1, 2026 | $2.2B | 30 | 9 |
| Merck & Co., Inc. | May 26, 2026 | $2.1B | 32 | 16 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $1.6B | 24 | 11 |
| Amgen Inc. | May 19, 2026 | $1.5B | 39 | 13 |
| Gilead Sciences, Inc. | April 30, 2026 | $1.2B | 32 | 12 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | Against | For |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | Against | For |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| May 19, 2026 | Amgen Inc. | Stockholder proposal to require an independent board chairman. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | Against | For |
| April 23, 2026 | Pfizer Inc. | Adopt an Independent Chair Policy Shareholder proposal | Against | For |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
Meetings with a proxy contest or competing nominees (3 in 2025-2026), and how the fund voted the items on its ballot.
6,461 ballot items at 428 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Vanguard Health Care Index Fund (VHT) voted at 428 shareholder meetings of 407 companies, on 6,461 ballot items in all. Where management made a recommendation, the fund followed it on 76.5% of the items and voted against it 1,305 times. Its most frequent area of disagreement was director elections (1,184 of its votes against management). It voted on 51 shareholder proposals. It voted FOR the board's own proposals less often than Vanguard's funds as a whole (91.8% against 94.5%). It voted differently from most Vanguard funds on 5 items. 3 of its meetings were contested.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Vanguard’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.